Cell line name |
HCC1954/TDR |
Accession |
CVCL_B3MM |
Resource Identification Initiative |
To cite this cell line use: HCC1954/TDR (RRID:CVCL_B3MM) |
Comments |
Population: East Indian. Selected for resistance to: DrugBank; DB05773; Trastuzumab emtansine (T-DM1). Derived from site: In situ; Breast; UBERON=UBERON_0000310. |
Sequence variations |
- Gene fusion; HGNC; 2092; CLTC + HGNC; 29559; VMP1; Name(s)=CLTC-VMP1 (from parent cell line).
- Mutation; HGNC; 8975; PIK3CA; Simple; p.His1047Arg (c.3140A>G); ClinVar=VCV000013652; Zygosity=Heterozygous (from parent cell line).
- Mutation; HGNC; 11998; TP53; Simple; p.Tyr163Cys (c.488A>G); ClinVar=VCV000127814; Zygosity=Homozygous (from parent cell line).
|
Disease |
Breast ductal carcinoma (NCIt: C4017) |
Species of origin |
Homo sapiens (Human)
(NCBI Taxonomy: 9606) |
Hierarchy |
Parent: CVCL_1259 (HCC1954) |
Sex of cell |
Female |
Age at sampling |
61Y |
Category |
Cancer cell line |
Publications | CLPUB00650 Sabbaghi Mehrjardi M.A. Uncovering mechanisms of acquired resistance to trastuzumab-emtansine (T-DM1) in HER2 positive breast cancer. Thesis PhD (2017); Universitat de Barcelona; Barcelona; Spain PubMed=28821558; DOI=10.1158/1078-0432.CCR-17-0696 Sabbaghi Mehrjardi M.A., Gil-Gomez G., Guardia C., Servitja S., Arpi O., Garcia-Alonso S., Menendez S., Arumi-Uria M., Serrano L., Salido M., Muntasell A., Martinez-Garcia M., Zazo S., Chamizo C., Gonzalez-Alonso P., Madoz-Gurpide J., Eroles P., Arribas J., Tusquets I., Lluch A., Pandiella A., Rojo F., Rovira A., Albanell J. Defective cyclin B1 induction in trastuzumab-emtansine (T-DM1) acquired resistance in HER2-positive breast cancer. Clin. Cancer Res. 23:7006-7019(2017) |
Cross-references |
Cell line databases/resources |
cancercelllines; CVCL_B3MM
|
Encyclopedic resources |
Wikidata; Q110432840
|
Entry history |
Entry creation | 16-Dec-2021 |
Last entry update | 05-Oct-2023 |
Version number | 6 |
---|